Accuray heads into the back half of May with a shattered price, no remaining buy ratings, and a stock that has erased two-thirds of its value in under a month.
The defining moment came on May 6 when Accuray reported earnings and the stock fell 36% in a single session. It never recovered. By Friday's close it was trading at $0.27 — down 29% on the week and 33% on the month. The collapse has now attracted a wave of analyst capitulation that sets up a starkly different conversation heading into the August print.
The Street turned uniformly cautious in the days following the results. Jefferies downgraded to Hold on May 12, cutting its price target from $3.50 all the way to $0.35 — a 90% reduction that underlines just how dramatically the investment case changed on earnings day. BTIG moved to Neutral on May 7, removing its Buy rating with no updated target, signalling that even the stock's most persistent advocate no longer sees a near-term entry. The consensus now stands at two Holds and zero Buys, with a mean target of $0.35. The bull case rests on Accuray's CyberKnife and Stellar adaptive radiotherapy platform, and a newly announced 10-year research collaboration with the University of Wisconsin-Madison announced Friday. The bear case is more immediate: revenue decline, missed expectations, no clear path to profitability, and ongoing geopolitical headwinds affecting commercial execution.
Short positioning tells a more complicated story. Short interest fell sharply in the days after the earnings print — down 12% on the week to 5.7% of the free float, as some short sellers covered into the collapse. The move looks like profit-taking rather than a change in sentiment. By Thursday, May 14, short interest ticked back up 6.8% in a single day, recovering a portion of the prior week's unwind. Borrow costs remain almost trivially low at 0.67% annualised, down 39% over the past month — there is no squeeze pressure here. Availability in the lending market is generous, with the borrow pool far from stressed. The ORTEX short score eased to roughly 51 from a recent high of 56 before the print; it has started climbing again this week.
Options positioning is technically elevated relative to recent norms — the put/call ratio has moved to 0.061, nearly two standard deviations above its 20-day average of 0.052 — but those figures reflect how starved of puts this name is in absolute terms. The 52-week high on the PCR is 0.59. The current reading is a fraction of that. Options traders are not rushing to hedge a $0.27 stock with meaningful put volume; the statistical elevation simply reflects that calls dominate the book almost entirely.
On ownership, director Steven Mayer stepped in as a buyer in February, accumulating roughly 250,000 shares across three days at prices between $0.53 and $0.56. That cluster now sits deeply underwater. Net insider activity over the last 90 days was a modest positive in share terms, but the CCO also sold 40,000 shares in late March at $0.39. None of the open-market insider activity has demonstrated conviction at current levels. Major institutional holders include BlackRock at 7.2% and Vanguard at 4.9%, largely passive positions that will move with any index review rather than as discretionary signals.
The next scheduled earnings event is August 12. Between now and then, the Wisconsin research partnership and any colour on bookings or backlog recovery will be the only substantive catalysts. With every active analyst now on Hold and the stock sitting just above $0.25, the August call is where the remaining fundamental debate will concentrate.
See the live data behind this article on ORTEX.
Open ARAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
